We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01914731
Recruitment Status : Completed
First Posted : August 2, 2013
Last Update Posted : July 19, 2016
Information provided by (Responsible Party):
Elizabeth L. Hohmann, MD, Massachusetts General Hospital

Brief Summary:

Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of an inoculum administered by frozen orally-administered capsules.

Subjects with recurrent/relapsing C. difficile infection will receive FMT via oral capsules

The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.

Condition or disease Intervention/treatment Phase
Clostridium Difficile Infection Drug: Fecal Microbiota Transplant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbiota Transplant (FMT) for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
Study Start Date : August 2013
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Arm Intervention/treatment
Experimental: Capsule
Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via frozen capsule
Drug: Fecal Microbiota Transplant
Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via frozen capsule
Other Names:
  • Poop transplant
  • Fecal bacteriotherapy

Primary Outcome Measures :
  1. Safety [ Time Frame: Up to 6 months post-FMT ]
    Safety is assessed by clinical symptoms, exam, signs (GI and systemic)

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: Up to 2 months post-FMT ]
    Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Patients with refractory, recurrent or relapsing C. difficile infection (CDI) defined as EITHER:

    • At least three episodes of mild-to-moderate CDI
    • At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity
    • One protracted episode of CDI, defined as at least 3 weeks of ongoing Grade 3 severe symptoms of CDI despite standard antimicrobial therapy for CDI
    • We expect that most, but not all, subjects will have tried and failed a taper of vancomycin.
  • Willingness to accept risk of unrelated donor stool
  • Age 7 and above. Seven is chosen as a lower limit based upon the legal age of assent. Based on the literature, most children aged 7 and above can be taught to swallow even large capsules through simple coaching techniques
  • Able to consent for self, or parental assent/child assent as age appropriate

Exclusion criteria

  • Delayed gastric emptying syndrome
  • Known chronic aspiration
  • Swallowing dysfunction or oral-motor dyscoordination.
  • Inability or unwillingness to swallow multiple large capsules
  • Pregnant women
  • Patients with an acute illness unrelated to CDI or an acute exacerbation of underlying comorbid condition
  • Patients with comorbidities associated with increased risk of serious infection following bacterial translocation, including but not limited to:

    • subjects on major immunosuppressive agents including high dose corticosteroids, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biologic agents, anti-TNF agents, and others; chemotherapeutic anti-neoplastic agents*
    • Patients with decompensated liver cirrhosis, advanced HIV/AIDS, recent bone marrow transplant, hypoglobulinemia or other cause of severe immunodeficiency*
  • Patients with a history of significant allergy to foods not excluded from the donor diet

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01914731

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Elizabeth Hohmann, MD Massachusetts General Hospital
Additional Information:
Layout table for additonal information
Responsible Party: Elizabeth L. Hohmann, MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01914731    
Other Study ID Numbers: 2013-P-001355
First Posted: August 2, 2013    Key Record Dates
Last Update Posted: July 19, 2016
Last Verified: July 2016
Keywords provided by Elizabeth L. Hohmann, MD, Massachusetts General Hospital:
Fecal Microbiota Transplant
Clostridium difficile
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Clostridium Infections
Disease Attributes
Pathologic Processes
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses